...EMA's CHMP recommended expanding the label of Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include... ...II diabetes in combination with other glucose lowering treatments, including basal insulin, when use of Bydureon... ...metformin and a thiazolidinedione. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bydureon exenatide Business: Endocrine/Metabolic
Chris Lieu
Bydureon
exenatide
AstraZeneca...
...Data published in The Lancet showed that diabetes drug Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN... ...EXENATIDE-PD trial to treat moderate Parkinson’s disease. In the 60-patient trial, once-weekly 2 mg subcutaneous Bydureon... ...a longer-term study with more participants” to evaluate Bydureon's effect on quality of life (QOL). Bydureon...
...marketed for Type II diabetes. AstraZeneca plc , 3SBio Inc. and Alkermes plc market Bydureon (Byetta LAR... ...a long-acting release (LAR) formulation of exenatide, for Type II diabetes. Bristol-Myers Squibb Co. has Exenatide once weekly...
...as Brilique . Harvard Pilgrim also signed a three-year contract for Type II diabetes treatment Bydureon... ...LAR ) formulation of Byetta exenatide, a synthetic exendin-4 . The insurer will pay for Bydureon... ...LSE:AZN; NYSE:AZN), London, U.K. Harvard Pilgrim Health Care Inc. , Boston, Mass. Business: Cardiovascular, Endocrine/Metabolic
Alex Himes
Brilinta
Bydureon
Harvard...